ArticleEuropean journal of nuclear medicine and molecular imaging2020
Staging FDG PET-CT changes management in patients with gastric adenocarcinoma who are eligible for radical treatment.
Article in European journal of nuclear medicine and molecular imaging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Korean Practice Guidelines for Gastric Cancer 2024: An Evidence-based, Multidisciplinary Approach (Update of 2022 Guideline).Journal of gastric cancer · 2025Guideline
- Association between neutrophil-lymphocyte ratio and lymph node metastasis in gastric cancer: A meta-analysis.Medicine · 2022Pooled it
- Can the BMI-based dose regimen be used to reduce injection activity and to obtain a constant image quality in oncological patients byEuropean journal of nuclear medicine and molecular imaging · 2021Trial
- A pretreatmentTranslational cancer research · 2026Article
- Molecular Imaging in Gastric Cancer: [¹⁸F]FDG and Fibroblast Activation Protein-Targeted PET/CT.Journal of gastric cancer · 2026Review
- Predictive Value of Preoperative [International journal of general medicine · 2025Article
- Clinical applications of fibroblast activation protein inhibitor positron emission tomography (FAPI-PET).Npj imaging · 2024Review
- Impact ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- Different hydration protocols for the quantification of healthy tissue uptake of half-doseQuantitative imaging in medicine and surgery · 2023Article
- Head-to-Head Comparison of FDG and Radiolabeled FAPI PET: A Systematic Review of the Literature.Life (Basel, Switzerland) · 2023Review
- pH-sensitive gold nanoclusters labeling with radiometallic nuclides for diagnosis and treatment of tumor.Materials today. Bio · 2023Article
- Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach.Journal of gastric cancer · 2023Review
- Predicting the Recurrence of Gastric Cancer Using the Textural Features of Perigastric Adipose Tissue on [International journal of molecular sciences · 2022Article
- The feasibility of ultralow-activityAnnals of nuclear medicine · 2022Article
- PET/CT for Predicting Occult Lymph Node Metastasis in Gastric Cancer.Current oncology (Toronto, Ont.) · 2022Review
- The Visible Stomach: Elusive Diffuse-Type Adenocarcinoma Presents With Gastric Outlet Obstruction.Cureus · 2022Article
- The predictive value of total-body PET/CT in non-small cell lung cancer for the PD-L1 high expression.Frontiers in oncology · 2022Article
- Article
- Acceptance and disparities of PET/CT use in patients with esophageal or gastro-esophageal junction cancer: Evaluation of mature registry data.Frontiers in nuclear medicine · 2022Article
- Head-to-head comparison of [European journal of nuclear medicine and molecular imaging · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
aim18-fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET-CT) is valuable in the management of patients with oesophageal cancer, but a role in gastric cancer staging is debated. Our aim was to review the role of FDG PET-CT in a large gastric cancer cohort in a tertiary UK centre.
methodsWe retrospectively reviewed data from 330 patients presenting with gastric adenocarcinoma between March 2014 and December 2016 of whom 105 underwent pre-treatment staging FDG PET-CT scans. FDG PET-CT scans were graded qualitatively and quantitatively (SUV
resultsOf the 105 patients (74 M, median age 73 years) 86% of primary tumours were metabolically active (uptake greater than normal stomach) on FDG PET-CT [41/44 (93%) of the intestinal histological subtype (SUV
conclusionFDG PET-CT provides new information in a clinically useful proportion of patients, which leads to changes in treatment strategy, most frequently by detecting previously unidentified metastases, particularly in those with intestinal-type tumours.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.